Swiss pharmaceutical manufacturer Lonza Group AG on Monday confirmed it is in advanced talks with private equity firm KKR & Co LP to acquire Capsugel, a U.S. maker of capsule products and other drug delivery systems.
Sources familiar with the talks told Reuters that a potential transaction would be valued at more than $5 billion.
Capsugel "would fit perfectly with Lonza's ... strategy and strengthen its position as leading supplier to a number of important healthcare markets," Lonza said in a statement.
Sources familiar with the talks told Reuters that a potential transaction would be valued at more than $5 billion.
Capsugel "would fit perfectly with Lonza's ... strategy and strengthen its position as leading supplier to a number of important healthcare markets," Lonza said in a statement.
